Show Notes
(
0:32):
Before we get started, Dr. McKeon, could you please tell our listeners a little bit about yourself and your background?
(
01:13)
How long have you been with the lab?
(
01:37)
Could you describe which patients should have this testing and when should it be performed?
(
01:50)
Can you tell us a little bit about this unique assay that has not only glycine receptor but also other antibody tests?
(
03:12)
We offer this evaluation in both serum and CSF. Can you offer any guidance about when one is more appropriate than the other?
(
04:37)
Four different antibodies are included in the stiff-person assay. Why is it most appropriate to evaluate all four? And why is this assay separate from our movement disorder evaluation that includes 20 different antibodies?
(
06:19)
Is it important to include all relevant antibodies — but not those would lead physicians down a confusing path?
(
07:50)
Can you give our listeners a couple examples of patient presentations that might lead a physician to order this evaluation, and a couple examples where it wouldn't be appropriate?
(
09:59)
Can you give a couple examples of when a broader movement disorder evaluation would be appropriate?
(
11:11)
How does this new stiff-person evaluation improve upon previous approaches? What will this new test offer to physicians?
(
12:35)
What does a positive or negative stiff-person evaluation result mean for a patient's care?
(
13:25)
How do alanine receptor positivity and immune responsiveness affect a patient's prognosis?
(
13:58)
Can tests other than this offering from Mayo Clinic Laboratories give physicians the same answers?
(
14:44)
What is the key takeaway about this test?